STAT: RNA firm GreenLight Biosciences to go public in $1.2 billion deal

STAT covers the $1.2 billion deal that sees Greenlight Biosciences go public

Massachusetts-based synthetic biology company, GreenLight Biosciences, whose research ranges from developing pesticide alternatives for crops to a Covid-19 vaccine candidate plans to go public to advance its RNA manufacturing platform. Read an extract from STAT’s report below:

GreenLight says its proprietary manufacturing platform allows it to make RNA more efficiently than other companies, so it is partnering with other firms while also developing its own RNA-based products. Those partners include academic research institutions and companies in the agricultural, pharmaceutical, consumer goods, and energy industries.

The company said has 14 products in its pipeline, including a COVID-19 vaccine candidate, a vaccine for influenza, and a gene therapy for sickle cell disease. The COVID-19 vaccine is expected to enter human clinical trials early next year.

On the agriculture side, one of GreenLight’s most advanced products is an RNA-based pesticide intended to protect honeybees from parasitic mites, a program it licensed from Bayer that is expected to launch in 2024.

Read the full article here.

Find out more about how GreenLight manufactures RNA here.